GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Status:
Completed
Trial end date:
2006-10-25
Target enrollment:
Participant gender:
Summary
This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease).
This study will last up to 56 weeks, and subjects will visit the clinic 16 times. Subjects
will be given breathing tests, and will record their breathing symptoms daily on diary cards.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Salmeterol Xinafoate Xhance